It is well-known that EGFR participates in the development and progression of lung cancer [42], and its amplifications and mutations correlate with effective response to several EGFR tyrosine kinase inhibitors (TKIs) for NSCLC therapy [43]. Here, EGFR is linked to lung carcinoma.